Researchers are working to develop a potential lab test to diagnose preeclampsia-a serious complication often requires premature delivery and is sometimes fatal to both mother and fetus.
Researchers led by a team at Brown University and Women and Infants Hospital has also made a well-defined animal model of preeclampsia.
Advertisement"Our model is the first pregnancy-specific animal model and our predictive assay is the first one where we can go back to the first trimester and predict problems," said Surendra Sharma of the Brown University
Building on research linking the presence of the immune system secretion Interleukin-10 (IL-10) to a successful course of pregnancy, the researchers started experimenting with mice genetically engineered to lack IL-10.
They hypothesized that if they isolated blood serum from human patients with preeclampsia and gave a dose of it to the mice, the rodents would develop preeclampsia symptoms.
Just to be sure, the researchers gave the preeclampsia serum to mice that were not pregnant.
Nothing happened, confirming that the onset of preeclampsia symptoms in the engineered mice was a consequence of their pregnancy.
The significance of having an animal model for preeclampsia is that it will allow for experiments that can shed light on the cause of the disease and its progression, said Sharma.
After observing how preeclampsia serum caused disruption to the spiral arteries, the team reasoned that preeclampsia serum might also disrupt the formation of vasculature in the lab.
They created an in vitro culture of two key cell types involved in spiral artery development - endothelial cells and trophoblasts and then exposed some to serum from women with normal pregnancies and some to preeclampsia serum from women taken at various stages of their pregnancies.
The researchers found that vasculature developed normally in the presence of serum from women with normal pregnancies.
But they also found that preeclampsia serum taken from women as early as 12 to 14 weeks into their pregnancies, about 10 to 12 weeks before they were diagnosed with preeclampsia, was able to disrupt vascular formation.
"The idea is that we can predict preeclampsia ahead of time and women can be treated," added Sharma.
The findings were reported in The American Journal of Pathology.